Please use this identifier to cite or link to this item:
|Title:||Treatment of chronic hepatitis B virus infection using a mutant recombinant human β-interferon. A preliminary study|
|Authors:||Guan, R. |
|Source:||Guan, R., Ng, H.S., Yap, I., Leong, S.F., Colby, C.B., Wee, A., Ho, J., Tan, L.H., Smith, R. (1991). Treatment of chronic hepatitis B virus infection using a mutant recombinant human β-interferon. A preliminary study. Drug Investigation 3 (2) : 82-91. ScholarBank@NUS Repository.|
|Abstract:||17 patients (14 men and 3 women) aged 21 to 49 with chronic hepatitis B infection were treated with a 28-day course of human recombinant β-interferon (with the cysteine residue at position 17 substituted by serine to enhance specific activity and stability) [rINF-B(ser)] to determine its efficacy, acceptability and tolerability. All patients with HBeAg-positive with detectable HBV-DNA in their sera for at least 3 months prior to therapy. Eight patients were randomly selected to receive 6 million U/day of this interferon for 28 days while 9 others received 30 million U/day for 28 days. Serum HBV-DNA levels dropped in all patients during treatment and were undetectable at the end of treatment in 3 of 9 (33%) patients receiving 30 million U/day. HBV-DNA reappeared in all 3 patients during follow-up but became undetectable again at 16 and 18 months after therapy. Serum HBV-DNA levels became undetectable in 2 other patients receiving 30 million U/day during followup and one of them became seronegative for HBeAg 10 months after treatment. Two of 8 patients receiving 6 million U/day had transient loss of serum HBV-DNA following treatment. No changes in liver histology were noted immediately after treatment. Adverse effects of therapy included fever, malaise and weight loss. Neutropenia necessitating dosage reduction was noted in 7 patients (5 of them were receiving 30 million U/day interferon). Human rINF-B(ser) is effective in reducing viral replication in chronic hepatitis B virus infection, but the optimal dose and duration of treatment for permanent elimination of viral replication is yet to be determined.|
|Source Title:||Drug Investigation|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 13, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.